In addition to exploring existing drugs for multiple indications, United Therapeutics (UTHR) has been actively investing in research and development (or R&D) programs involving novel technologies. These are targeted toward pulmonary arterial hypertension (or PAH), cancer, and the orphan disease bronchopulmonary dysplasia (or BPD).
A day in the life at Startup Village is hectic with the University of Maryland students and alumni working on business projects from 8 a.m. to as late as midnight. It’s not uncommon for collaborators to crash on the couch, said David Engle, co-founder and executive director of Startup Village and a 2015 spring graduate of this university.
Submit your proposal today for the “Make Your Medical Device Pitch for Kids!” competition. Up to six prizes totaling $250,000 will be awarded to the winning presentations at the 4th Annual Pediatric Surgical Innovation Symposium in Washington, DC hosted by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company’s proprietary molecule Thymosin beta 4 (Tβ4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026.
Maryland is a leader in National Institutes of Health funding for biomedical research and in venture capital investment for bioscience-related companies, according to a recent study from the Biotechnology Innovation Organization.
The bioscience industry employs more than 34,000 people in Maryland, and the average annual wage for a bioscience worker in the United States reached $94,543 in 2014, according to the report.
The National Creativity Network (NCN) is pleased to announce the winner of the 2016 USA Creative Business Cup – Kitchology of Germantown, MD. Kitchology (www.kitchology.com) is the first company to create an integrated social cooking platform for the estimated 160 million people dealing with special diets and the suppliers who sell to them. It allows consumers to overcome the limitations imposed by food restrictions, and makes it easy for like-minded cooks to find each other. Kitchology applies machine learning to nutrition science, profiling and social curation to help the home cook match and modify recipes to satisfy the challenges of food allergies, intolerances, and special diets. Kitchology enables meal planning based on ingredients previously used and explored, personalized ingredient substitutions, purchasing with intelligent shopping lists, step-by-step cooking, and fosters influencer relationships.
Eli Lilly ($LLY) has been doubling down on its efforts to invent new animal vaccines–opening a 48,000-square-foot research facility near its Indianapolis headquarters, for example, that its animal health division, Elanco, will use for R&D. On the production-animal side of the business, Elanco’s bread and butter until now has been cattle and swine products, but the company is looking to expand into a rapidly growing corner of food production where it has had virtually no presence: aquaculture.
With concerns over a continued Zika outbreak growing, the Food and Drug Administration has given Roche Holdings emergency approval to use one of its Zika blood testing kits.
The approval, which lasts as long as the emergency is ongoing, will allow for testing of the virus through Roche’s LightMix Zika rRT-PCR test, which has not been approved by the FDA yet.
Summer is a good time to review investment activity for pharmaceutical and biotech companies in the year so far and a new report shows that there’s still life for life science IPOs.
The U.S. Food and Drug Administration on Monday issued emergency authorization for a Zika diagnostics test from Swiss drugmaker Roche, skirting normal approval channels as the regulator moves to fight the disease’s spread.
